The frequency of agitation due to inappropriate use of naltrexone in addicts

Authors
Sima Siadat
Nastaran Eizadi-Mood
Ali Mohammad Sabzghabaee
Farzad Gheshlaghi
Department of Clinical Toxicology, Isfahan Clinical Toxicology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: There is a high tendency among specialists to treat the addicts with naltrexone; withdrawal symptoms are frequent after taking naltrexone along with opioids. This study investigated the frequency of agitation due to inappropriate use of naltrexone in addicts.
Materials and Methods: This was a cross-sectional study, conducted in Noor and Aliasghar hospitals in Isfahan city. The study population included the addicts who were agitated as a result of naltrexone abuse. Scores of patients with agitation were measured with Richmond Agitation Sedation Scale (RASS). Patient outcomes including recovery without complications, recovery with complications (rhabdomyolysis), and mortality were recorded.
Results: All the patients with agitation caused by naltrexone abuse during 1 year were 40 people, of whom nine were excluded due to their comorbid diseases (diabetes or cardiovascular disease). Among the remaining 31 patients, 30 were male. The patients' mean age was 29.93 (5.24) years. The most common symptoms observed besides agitation was midriasis (41.9%), and vomiting (41.9%), A 38.8% of the patients scored 3 or 4, and, 61.2% scored 1 or 2 for agitation. The mean time for patients' restlessness scores to reach zero was 9.30 (3.71) h (min: 3 h, max: 18 h). All the patients in both groups were discharged with recovery without complication.
Conclusion: Considering the high prevalence of agitation in the poisoning emergency department due to inappropriate use of naltrexone, more accurate planning for administration of naltrexone in addicts seems necessary.

Keywords

1.
Ferrari A, Bertolotti M, Dell'Utri A, Avico U, Sternieri E. Serum course of naltrexone and 6 beta-naltrexone levels during long-term treatment in drug addicts. Drug Alcohol Depend 1998;52:211-20.  Back to cited text no. 1
    
2.
Littleton J, Zieglgansberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 2003;12:3-11.  Back to cited text no. 2
    
3.
Kleber HD. Pharmacologic treatments for opioid dependence: Detoxification and maintenance options. Dialogues Clin Neurosci 2007;9:455-70.  Back to cited text no. 3
    
4.
Krupitsky EM, Zvartau EE, Masalov DV, Tsoy MV, Burakov AM, Egorova VY, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat 2006;31:319-28.  Back to cited text no. 4
    
5.
O'Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. JAMA 1998;279:229-34.  Back to cited text no. 5
    
6.
Boyce SH, Armstrong PAR, Stevenson J. Effect of inappropriate naltrexone use in a heroin misuser. Emerg Med J 2003;20:381-2.  Back to cited text no. 6
    
7.
Lobmaier P, Gossop M, Waal H, Bramness J. The pharmacological treatment of opioid addiction: A clinical perspective. Eur J Clin Pharmacol 2010;66:537-45.  Back to cited text no. 7
    
8.
Mannelli P, De Risio S, Pozzi G, Janiri L, De Giacomo M. Serendipitous rapid detoxification from opiates: The importance of time-dependent processes. Addiction 1999;94:589-91.  Back to cited text no. 8
    
9.
De Giacomo M, Gaspari R, Stefanelli A, Barelli A, Mannelli P. Emergency therapeutical approach simulating ultrarapid opioid detoxification in methadone withdrawal precipitated by erroneous administration of naltrexone. Eur J Emerg Med 1999;6:153-5.  Back to cited text no. 9
    
10.
Bristow K, Meek M, Clark N. Acute opioid withdrawal in the emergency department: Inadvertent naltrexone abuse. Emerg Med 2001;13:359-63.  Back to cited text no. 10
    
11.
Quigley MA, Boyce SH. Unintentional rapid opioid detoxification. Emerg Med J 2001;18:494-5.  Back to cited text no. 11
    
12.
Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, et al. Clinical guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002;30:119-41.  Back to cited text no. 12
    
13.
Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et al. The Richmond Agitation-Sedation Scale: Validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002;166:1338-44.  Back to cited text no. 13
    
14.
Pinelli A, Cighetti G, Trivulzio S. Plasma malondialdehyde levels and opiate withdrawal signs observed in rats treated with morphine plus naloxone: Effects of alpha-lipoic acid administration. Fundam Clin Pharmacol 2008;22:439-45.  Back to cited text no. 14
    
15.
Ruan X, Chen T, Gudin J, Couch JP, Chiravuri S. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): Case report and the focused review of the literature. J Opioid Manag 2010;6:300-3.  Back to cited text no. 15
Advanced Biomedical Research
Volume 2014, December
December 2014
Pages 1-4